Stručni rad

https://doi.org/10.15836/ccar2020.270

The Efficacy and Safety of Single-pill Combination of Amlodipine/ valsartan (Wamlox®) and Amlodipine/valsartan/hydrochlorothiazide (Valtricom®) in Patients with Grade 2 or 3 Arterial Hypertension – the VICTORY II Study

Aleša Primožič ; Krka, d. d., Novo mesto, Slovenija
Alenka Glavač Povhe ; Krka, d. d., Novo mesto, Slovenija
Mateja Grošelj ; Krka, d. d., Novo mesto, Slovenija
Breda Barbič-Žagar orcid.org/0000-0002-1173-7361 ; Krka, d. d., Novo mesto, Slovenija

Sažetak

Hypertension is the leading cause of cardiovascular (CV) morbidity and mortality worldwide. In spite of many different recommendations and actions related to screening and management of hypertension, reaching target levels of blood pressure (BP) is still a challenge in clinical practice. The main goal of treating patients with hypertension remains the maximum reduction in the risk of fatal and non-fatal CV complications, cerebrovascular complications, and chronic kidney disease. To achieve this goal, it is necessary to lower BP to target levels. In addition to lifestyle changes, effective antihypertensive medication is needed. The VICTORY II study was performed to assess the efficacy and safety of the use of single-pill combinations (SPCs) of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in achieving the target level of BP in newly diagnosed or uncontrolled patients with grade 2 or 3 arterial hypertension. A total of 100 patients were enrolled in this multicenter, open, prospective clinical study. All patients with grade 2 hypertension started the treatment with SPC of amlodipine/valsartan, 5 mg/80 mg, which if necessary could be up titrated step-by-step to the final option, i.e. SPC of amlodipine/valsartan/ hydrochlorothiazide 10/160/12.5 mg, to achieve target levels of BP. Patients with grade 3 hypertension started the treatment with SPC of amlodipine/valsartan 5 mg/160 mg, which could be up-titrated step-by-step to SPC of amlodipine/valsartan/hydrochlorothiazide 10/160/25 mg if necessary to achieve target levels of BP. The results of the VICTORY II study showed that SPCs of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide effectively reduce BP in patients with grade 2 or 3 hypertension and have a good tolerability profile.

Ključne riječi

arterial hypertension; efficacy, safety; single-pill combination; amlodipine/valsartan; amlodipine/valsartan/hydrochlorothiazide

Hrčak ID:

242969

URI

https://hrcak.srce.hr/242969

Datum izdavanja:

28.8.2020.

Podaci na drugim jezicima: hrvatski

Posjeta: 3.317 *